At the last check on Thursday, Mesoblast Limited’s (NASDAQ:MESO) stock was up $0.2, moving up 13.99 percent to $1.63. The average number of shares traded per day over the past five days has been 382,628 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0450 fall in that time frame. In the last twenty days, the average volume was 1,069,942, while in the previous 50 days, it was 643,311.
Since last month, MESO stock retreated -59.25%. Shares of the company fell to $1.1552 on 08/11/23, the lowest level in the past month. A 52-week high of $5.12 was reached on 07/17/23 after having rallying from a 52-week low of $1.16. Since the beginning of this year, MESO’s stock price has dropped by -43.99% or -$1.3150, and marked a new high 21 times. However, the stock has declined by -68.16% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
The stock’s beta is 3.33. Besides these, the trailing price-to-sales (P/S) ratio of 37.82, the price-to-book (PB) ratio of 0.50.
Financial Health
In the three months ended June 29, Mesoblast Limited’s quick ratio stood at 1.10, while its current ratio was 1.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.22, and the total debt-to-equity ratio was 0.24. Based on annual data, MESO earned -$20.54 million in gross profit and brought in $10.21 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -12.20%. Return on equity (ROE) for the past 12 months was -16.30%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. MESO’s revenue rose 26.93% during the quarter, while net income inched up to $10.21 million. While analysts expected Mesoblast Limited to report -$0.15 quarterly earnings, the actual figure was -$0.14 per share, beating the consensus estimate by 6.70%. During the quarter, the company generated -$12.67 million in EBITDA. The liabilities of Mesoblast Limited were 168.27 million at the end of its most recent quarter ended June 29, and its total debt was $114.61 million.
Technical Picture
This quick technical analysis looks at Mesoblast Limited’s (MESO) price momentum. With a historical volatility rate of 100.47%, the RSI 9-day stood at 43.02% on 30 August.
With respect to its five-day moving average, the current Mesoblast Limited price is down by -2.74% percent or -$0.0450. At present, MESO shares trade -60.03% below its 20-day simple moving average and -49.84% percent below its 100-day simple moving average. However, the stock is currently trading approximately -60.03% below its SMA50 and -46.66% below its SMA200.
Stochastic coefficient K was 56.00% and Stochastic coefficient D was 55.15%, while ATR was 0.2029. Given the Stochastic reading of 70.47% for the 14-day period, the RSI (14) reading has been calculated as 35.95%. As of today, the MACD Oscillator reading stands at -0.0133, while the 14-day reading stands at 0.0770.
Analyst Ratings
Jefferies upgraded its rating on Mesoblast Limited (NASDAQ: MESO) to a Buy in a note to investors on Aug-31-23. The analysts firm previously had a Hold rating on the stock.Mesoblast Limited (MESO) has been rated Hold by analysts. According to 1 brokerage firm, MESO is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Mesoblast Limited stock as buy, with 2 recommending it as overweight.
With a median target price of $2.30, the current consensus forecast for the stock is $1.50 – $17.00. Based on these forecasts, analysts predict Mesoblast Limited (MESO) will achieve an average price target of $5.84.
